Treatment of Severe Fatigue and Hepatomegaly from Fatty Liver Disease

Initial Assessment and Risk Stratification

The American Association for the Study of Liver Diseases recommends excluding secondary causes of liver disease, including hepatitis C, excessive alcohol use, hepatotoxic medications, hypothyroidism, Wilson's disease, hemochromatosis, and celiac disease, before initiating treatment for fatty liver disease 4, 5
The European Association for the Study of the Liver suggests assessing metabolic risk factors, including diabetes, hypertension, dyslipidemia, and features of metabolic syndrome, in patients with fatty liver disease 4, 2
The American College of Gastroenterology recommends stratifying fibrosis risk using the FIB-4 score or liver stiffness measurement by transient elastography, with patients having intermediate or high-risk scores requiring hepatology referral for specialized management 3, 6

The American Heart Association recommends a weight loss target of 7-10% to improve steatohepatitis and fibrosis, which are the primary drivers of disease progression, with a weight loss of 5% improving hepatic steatosis 1, 2, 3
The Academy of Nutrition and Dietetics suggests a Mediterranean diet, featuring daily consumption of vegetables, fruits, fiber-rich cereals, nuts, fish or white meat, and olive oil, to improve liver disease outcomes 3, 6
The American College of Sports Medicine recommends 150-300 minutes of moderate-intensity exercise or 75-150 minutes of vigorous-intensity exercise per week to improve liver disease outcomes, with vigorous activity required for fibrosis improvement 1, 2, 3, 6

The American Diabetes Association recommends optimizing glycemic control with tight glucose management, with GLP-1 receptor agonists and SGLT2 inhibitors providing additional benefits for patients with diabetes and hepatic steatosis 5, 6
The American College of Cardiology suggests that statins are safe and effective for managing dyslipidemia in fatty liver disease patients and should not be withheld due to concerns about hepatotoxicity 3, 6, 7

The American Association for the Study of Liver Diseases recommends that pharmacological treatments aimed primarily at improving liver disease should be limited to patients with biopsy-proven NASH and fibrosis (≥F2) 1, 2

The American College of Gastroenterology recommends annual follow-up with repeated non-invasive tests, such as FIB-4 and liver stiffness measurement, for low-risk patients, and more frequent monitoring every 6 months for intermediate and high-risk patients 3
The American Association for the Study of Liver Diseases suggests screening for hepatocellular carcinoma and gastroesophageal varices in patients with cirrhosis, and screening for varices in patients with liver stiffness ≥20 kPa or thrombocytopenia 3